Company intelligence / Profile preview

Peltrade

Jupiter / Durham, Florida / North Carolina, United Statespelthos.com ↗

Ownership: Private
Development stage: Commercial

Overview

ZELSUVMI (berdazimer) topical gel, 10.3%, developed using the proprietary NITRICIL nitric oxide-based platform, is the first and only FDA-approved topical prescription medication for molluscum contagiosum that can be applied at home. It has received Novel Drug designation from the FDA and will be commercially available in late 2024. Clinical results have demonstrated efficacy and safety in both adults and pediatric patients one year of age and older.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeNitric oxide releasing agent
Industry: Biotech

Drug pipeline

1 asset

ZELSUVMI

Commercial

Indications: Molluscum contagiosum

Partnerships

Ligand intends to commercialize ZELSUVMI with a capital provider or strategic partner but no specific partners named yet

Beyond the preview

Go deeper on Peltrade.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peltrade.

Explore the full profile